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Diabetes is a very common cause of peripheral neuropathy, and there is no optimal intervention universally accepted by clinicians.
Monochromatic infrared photo energy is a relatively new modality used in the United States for reducing pain and increasing cir-
culation. This study investigated the eﬀects of monochromatic infrared photo energy on reducing pain, improving sensation, and
increasing balance in patients with diabetic peripheral neuropathy. Thirty-ﬁve patients with diabetic peripheral neuropathy com-
pleted the program and were randomly assigned into two groups. Group 1 (experimental, n = 18) received monochromatic
infrared photo energy, therapeutic exercises, and balance training. Group 2 (control, n = 17) received therapeutic exercises and
balance training. Both groups received three treatment sessions per week for 4 weeks. Outcome included pain intensity measured
on a visual analogue scale, sensation measured with the Semmes-Weinstein monoﬁlament 5.07, and balance measured with the
Berg score, before and after the 12 therapy sessions (1 month after the start of the intervention). Analysis of covariance tests
revealed statistically signiﬁcant improvements, speciﬁcally, P = .01, .014, and .0001, for pain, sensation, and balance, respectively,
in the experimental group. Within the limitations of this study, monochromatic infrared photo energy may play a role in treating
diabetic peripheral neuropathy by reducing pain, improving sensation, and increasing balance.
1.Introduction
Diabetic peripheral neuropathy (DPN) is a common pro-
gressive complication of diabetes mellitus [1], and it may
result, in part, from microvascular dysfunction. DPN rep-
resents a huge economic burden to the health care system
and is prevalent worldwide [2]. Peripheral neuropathy is also
linked to substantial reductions in the quality of life, and
the condition is associated with diabetes mellitus and other
metabolic diseases, chemotherapy, alcohol abuse, infection,
environmental toxins or drugs, scar tissue formation fol-
lowing surgery or radiation, as well as idiopathic causes
[3, 4]. Approximately 15% of the population over 40 years
of age experiences peripheral neuropathy, and, in those with
diabetes, the prevalence is approximately 29% [5]. Of these
patients, about 50% are insensitive to the 5.07 Semmes-
Weinstein monoﬁlament (SWM) at two or more of six
measured plantar sites [5]. Despite the prevalence of DPN,
many patients are asymptomatic and therefore do not seek
care for it [5].
Patients with early DPN usually experience pain that
worsens at night: perceived numbness, and a tingling sensa-
tion in the feet and hands. Patients may show reduced ability
to detect temperature changes and/or pressure in the feet
in advanced stages, and these symptoms are associated with
postural instability, loss of leg and foot strength, and reduced
proprioceptive thresholds in foot inversion, eversion, plantar
ﬂexion, and dorsiﬂexion [6]. Therefore, patients with DPN
often develop gait and balance dysfunction that leads to
an increased risk of falling, foot ulcers, and amputations.
Consequently, patients are often encouraged to use compen-
satory strategies such as walking aids (cane or walker), and
learn about palliative and protective foot care in an eﬀort to
identify potential environmental hazards that could lead to
pedal cutaneous compromise or injury.2 ISRN Rehabilitation
Although there is no deﬁnitive intervention for the treat-
ment of DPN, the mainstay generally hinges on rigorous gly-
cemiccontrolandreductionofpainandparesthesiabyeither
topical or systemic means [6]. Therefore, there is a need for
a complementary approach to help improve circulation and
reduce pain to be used along with medications.
Various types of electrotherapy, such as transcutaneous
electrical nerve stimulation (TENS), pulsed electromagnetic
ﬁelds (PEMF), static magnetic ﬁeld therapy, external mus-
cle stimulation, and frequency-modulated electromagnetic
neural stimulation, have been reported to decrease pain
and increase circulation. However, results of the studies
describing the eﬀects of these modalities on peripheral neu-
ropathy remain controversial, and randomized-controlled
studies with larger sample sizes and long followup periods
are needed in order to better elucidate the eﬃcacy of these
modalities. And, although electrotherapy modalities may
help decrease pain [7], they do not restore blood ﬂow, which
may limit their ability to improve sensation. Therefore, there
is a need for a modality that works to restore blood ﬂow.
Monochromatic infrared photo energy (MIPE) repre-
sents another approach to the management of DPN. MIPE
was cleared by the United States Food and Drug Administra-
tion in 1994 for increasing circulation and reducing pain.
MIPE at a wavelength of 890nm is produced by an array of
60 gallium aluminum arsenide light-emitting diodes located
on ﬂexible pads and the near infrared photo energy is
delivered in a noninvasive, drug-free manner. The diode
array must be placed in direct contact with the target skin,
as MIPE energizes cells in the epidermis and the most super-
ﬁcial portion of the dermis, thereby warming the skin. The
890nm photo energy penetrates the skin enough to be
absorbed by hemoglobin in the rete capillary loops in the
papillary dermis, rather than just water in the more super-
ﬁcial layers [8]. At 890nm, MIPE was shown to increase
the concentration of plasma nitric oxide in nondiabetic
volunteers and increasing the microcirculation [9, 10], and
it has, in fact, been shown to reduce the incidence of
new foot wounds in elderly patients with diabetes mellitus
[11].
A few studies have investigated the eﬃcacy of MIPE
at reducing pain, improving foot sensation, and increasing
balance in patients with peripheral neuropathy. However,
we believe that the results of these previous studies were
adversely inﬂuenced by methodological limitations that
threatened the authors’ conclusions, including the lack of
a control group [12, 13]. Three retrospective observational
studies [14–16] showed MIPE to be eﬀective based on chart
review. Interestingly, a randomized controlled trial of photo
energy used at home failed to show the modality to be ther-
apeutically eﬀective [17]. In that particular study, moreover,
patients were trained to use a MIPE machine at home
and were evaluated before and after 90 days of treatment.
However, patient activities were not controlled and the
treatment was not supervised. Based on understanding of
the limitations of the previously published investigations, as
well as the purported eﬀects of photo energy on DPN, the
author undertook the investigation described in this report
inaneﬀorttotesttheresearchhypothesisthatMIPEcouldbe
used to reduce pain, improve sensation, and increase balance
in patients with DPN.
2.ParticipantsandMethods
2.1. Research Design. A randomized controlled study was
undertaken with participants randomly assigned to one of
twointervention groups: group1 receivedMIPE, therapeutic
exercises, and balance training, whereas the participants in
group 2 received therapeutic exercises and balance training
without MIPE. The duration of intervention was 4 weeks per
participant, and each participant was scheduled to undergo
3 therapy sessions per week. Measurements were taken at
b a s e l i n ea n da f t e re n do ft r e a t m e n t( 4w e e k s ) .
2.2. Participants. Participants were recruited from an outpa-
tient rehabilitation setting and were treated between Decem-
ber 2010 and April 2011. To be included in the study, partic-
ipants had to have diabetes mellitus, either type 1 or type 2.
ThemaximumallowableHbA1clevelrequiredforinclusions
was ≤7%. Furthermore, to be included, participants’ drug
regimen, as well as interventions to promote blood ﬂow in
the lower extremities, had to remain stable for one month
priortocommencementoftheinvestigation,andthroughout
the course of the investigation once the study commenced.
A 1-month washout period was also required for any
participant taking any drug aimed at promoting lower
extremity arterial perfusion. Still further, to be included,
participants had to have DPN as evidenced by insensitivity
to the 5.07SWM on at least 2 of 5 (great toe, fourth toe, and
3 of the 5 metatarsal heads) plantar surfaces of both feet.
The Berg balance score (BBS) [18] was used to measure
balance, and patients with scores ranging from 21 to 40
(medium fall risk) were considered eligible to participate in
the study. Patients were excluded from the study if they had a
history of knee or back surgery, or malignancy. All potential
subjects signed a consent form permitting the use of their
data for research purposes, and conﬁdentiality was assured
bytheuseofananonymouscodingsystem.Theconsentform
also included a clear explanation of the beneﬁts and expected
possible risks of the study, and the rights of human subjects
were protected at all times.
Participants who met the inclusion criteria were ran-
domly assigned to one of the two treatment groups. The
randomization process involved blank folders numbered
from 1 to 100 and containing hidden codes for group assign-
ment, and a random-number generator had determined the
codes. When a participant was eligible and gave consent to
participate, the investigator drew the next folder from the
ﬁle,whichdeterminedtreatmentallocation.Eachparticipant
was then tested using a visual analogue pain rating scale, the
5.07SWM, and the BBS.
Anindependentinvestigator,blindedtogroupallocation,
conducted the testing procedures. This investigator assessed
participants in both groups at both the initial and ﬁnal
sessions.Afterinitialtesting,participantsbegantheinterven-
tiononthesameday.Alicensedphysicaltherapistperformed
all interventions with the participants from both groups.
All participants underwent 3 sessions per week for 4 weeks.ISRN Rehabilitation 3
A coworker helped procure data used in this investigation by
taking measurements following the study protocol, although
that individual did not devise the study or participate in the
analysis or interpretation of the data.
2.3.Intervention. MIPEinterventionwasadministeredusing
theAnodyneTherapySystem,model480(AnodyneTherapy,
LLC, Tampa, FL). The device consisted of a base power unit
and 8 therapy pads, each containing 60 gallium aluminum
arsenide diodes. The area of light-emitting diodes per ther-
apy pad was 22.5cm2, yielding a total intervention area of
180cm2. The diodes delivered MIPE pulsed at 292Hz at a
wavelength of 890nm and provided an energy density of
62.4Joules/cm2 [8]. The participants in group 1 received
MIPE for 30 to 40 minutes per treatment session, and 4
therapy pads were placed on each lower extremity. The ther-
apist placed one pad at the medial and lateral aspect of each
leg immediately above the ankle, and one on the plantar and
one on the dorsal surface of each foot. Each subject sat com-
fortablyinaquietroomat21◦C,andtheskinoftheinterven-
tion area was covered with plastic wrap as a barrier between
the skin and the diodes to ensure compliance with infection
control procedures. The energy setting on the device was
preset at 10 bars for every patient, in accordance with the
manufacturer’s recommendations. The diodes and plastic
wrapwereremovedattheendofthetreatmentsession.Inter-
vention with MIPE was followed by a physical therapy
exercise program that focused on strengthening and balance
training (described below).
Participants in group 2 underwent only the physical
therapy that was the same regimen undertaken by the par-
ticipants in group 1. The physical therapy program included
static and dynamic balance retraining, as well as active lower
extremity strengthening (hip extensors, hip abductors, hip
adductors, quadriceps, ankle dorsiﬂexors) and stretching of
the hip, knee, and ankle ﬂexor musculature. Participants in
bothgroupswereeducatedastotherationaleforthetherapy,
and they received verbal and written instructions related to
the proper method of exercise, and they demonstrated to the
treating therapist their ability to properly perform the pre-
scribed exercises. All participants were instructed to exercise
at home on the days that they did not go to the clinic for
supervised intervention, and the home program was mon-
itored by asking the participants to record exercise using
weekly self-reported exercise logs.
2.4.OutcomeMeasurements. The10cmvisualanaloguepain
rating scale was used to measure neuropathic pain because it
is reliable and provides a valid assessment of pain intensity
[19]. Light touch sensation was assessed with use of the
5.07SWM [20], which is generally accepted as an eﬀective,
inexpensive, portable, painless, easy to administer, and reli-
ablescreeningmethodforassessingtouch-pressuresensation
in a valid fashion. In fact, the SWM was shown to be more
sensitive than the vibration perception threshold in measur-
ing peripheral sensation [21, 22]. The tester asked blind-
folded participants to indicate by stating the word—now
when and where on their foot they sensed the pressure of the
monoﬁlament. Ten speciﬁc anatomic sites were tested with
the monoﬁlament, including (1) the dorsal midfoot, (2–4)
the plantar aspect of the pulp of the ﬁrst, third, and ﬁfth
toes, (5–7) the plantar aspect of the ﬁrst, third, and ﬁfth
metatarsal heads, and (8–10) the medial and lateral aspects
of the midfoot (midtarsal joint) and the calcaneus. The tester
pressed the monoﬁlament at each site until the ﬁlament was
grossly observed to bend [20]. The assessor added the num-
ber of sites recognized by the participant, with a maximum
of 10 and a minimum of zero. Since previous research [23]
has shown that monoﬁlaments have variable accuracy and
durability with signiﬁcant reduction of the loading force
required to bend the ﬁlament after repetitive loading, we
replaced the monoﬁlaments after assessing every 10 partic-
ipants.
Balance was assessed using the BBS, which has been
shown to be reliable (intraclass interrater reliability correla-
tion coeﬃcient =.99) [18]. The BBS tests static and dynamic
balance activities and grades 14 items on a scale that ranges
from 0 to 4. A score between 21 and 40 indicates medium
balance impairment and fall risk. While a score below 20
indicates high balance impairement and fall risk. A score
between 41 and 56 indicates low balance impairement and
fall risk. The BBS testing involves the use of chairs with and
without arms, a stopwatch, a ruler, and a 6-inch step, and the
testmustbe completedwithina15-minute time limit [18].It
has been suggested that the BBS is the single best predictor of
the risk of falling [24]. These outcome measurements were
obtained a baseline, prior to intervention, and again at 4
weeks following the intervention.
2.5. Data Management and Analysis. Data analysis was per-
formed using SPSS for Windows, version 18.0. Data were
analyzed using the analysis of covariance (ANCOVA), with
the pretest (baseline) scores for the outcomes or interest as
the covariates. The ANCOVA was used to take into account
the baseline measurements for each patient. When baseline
information is available, this provides a more precise esti-
mate of the treatment eﬀect than either raw outcomes or
change scores [25]. Analyses of covariance were performed
to determine whether there is a diﬀerence between the two
groups on the posttest scores of pain as measured by the
visual analogue scale, light touch as measured by the 5.07
SWM, and balance as measured by the BBS. Demographic
characteristics of the participants were described in a statisti-
cal fashion, and the Bonferroni adjustment and the statistical
signiﬁcance was deﬁned at the 1.6% (P ≤ .016) level.
3. Results
A total of 41 patients met the inclusion criteria, including
18 (43.9%) males and 23 (56.1%) females. Of these, 10
(24.39%) had type 1 diabetes mellitus, and 31 (75.61%) had
type 2. Random allocation placed 21 (51.22%) into group 1
(to receive MIPE + training) and 20 (48.78%) into group 2
(training only). In group 1 (n = 21), there were 10 (47.62%)
males and 11 (52.38%) females, and in group 2 (n = 20),
there were 8 (40%) males and 12 (60%) females. Three
(14.29%) participants withdrew from the MIPE group, 1
(4.76%) due to the inability to arrange transportation (in4 ISRN Rehabilitation
Table 1: Physical characteristics of the participants (number = 35 participants)∗.
Variable Group 1—training + MIPE∧ (n = 18) Group 2—training only (n = 17) P value†
Age (years) 62.03 ± 11.01 59.4 ± 8.51
Height (cm) 161.34 ± 6.21 158.23 ± 5.82 >.05
Body weight (kg) 68.32 ± 10.19 73.1 ± 9.61
Body mass index (kg/m2) 24.25 ± 7.21 21.8 ± 4.14
∗Values are mean ± standard deviation.
∧MIPE: monochromatic infrared photo energy.
†Independent sample t-test revealed no statistically signiﬁcant diﬀerences between the treatment groups, as would be expected with random allocation of the
intervention.
essence, another scheduling problem), and 1 (4.76%) due to
scheduling diﬃculties, 1 (4.76%) due to the development of
congestive heart failure (CHF). In the training only group,
3 (15%) participants withdrew, 2 (10%) due to scheduling
diﬃculties (1 was too busy with work, and another had to
take care of a sick relative), and 1 (5%) for reasons that we
could not ascertain.
The loss of participants to follow up was associated with
diﬃculties primarily related to scheduling the intervention
sessions in both groups (2 (9.52%) of 21 in the MIPE group,
and 2 (10%) of 20 in the training only group), and for
scheduling conﬂicts in 2 other participants (the 1 (4.76%)
who developed CHF in the MIPE group and the 1 (5%) lost
for unknown reasons in the training only group). For these
reasons, a total of 35 participants, 18 (51.43%) in the MIPE
group and 17 (48.57%) in the training only group, were
included in the ﬁnal analysis.
Baseline demographic characteristics describing the par-
ticipants who completed the investigation are depicted in
Table 1. As expected with random allocation of the interven-
tion, there were no statistically signiﬁcant diﬀerences
between the treatment groups in regard to age, height, body
weight, and body mass index (P>. 05). Data were normally
distributed. Mean values and standard deviations of pain
intensity, sensation score, and balance score at baseline and
at 4 weeks are presented in Table 2. Table 2 depicts the
results of dependent samples t-tests comparing baseline to 4
week outcomes for pain, monoﬁlament sensation, and Berg
balance scores, within the intervention groups. These results
showed signiﬁcant diﬀerences in all dependent variables
before and after intervention in both groups (P ≤ .05). No
adverse events were observed or reported by any participant
in either intervention group.
Table 3 depictstheresultsoftheANCOVA,whichshowed
statistically signiﬁcant diﬀerences between the intervention
groups relative to pain (F1,32 = 8.16, P = .01), sensation
(F1,32 = 4.2, P = .014), and balance (F1,32 = 12.06, P =
.0001). The MIPE group displayed lower mean posttest pain
scores, fewer sites of pedal insensitivity as measured with the
5.07SWM, and higher mean Berg balance scores.
4. Discussion
All of the participants in this investigation showed reduction
in pain, increased foot sensation, and increased balance
scores, in both intervention groups, although the improve-
ments were statistically signiﬁcantly greater in the group of
participants that received MIPE (Tables 2 and 3). In regard
to pedal sensation, there was a decrease in number of sites
insensitive to the 5.07SWM in both intervention groups. In
the MIPE+ training group, the mean number of insensate
sites was 1.4 ± 2.1a f t e r4w e e k s ,c o m p a r e dt o7 .2 ± 1.8a t
baseline, and this diﬀerence was statistically signiﬁcant (P =
.025). In the training only group, the mean number of insen-
sate sites was 7.2 ± 1.3a f t e r4w e e k s ,c o m p a r e dt o8 .3 ± 0.9
atbaseline, andthis diﬀerence wasnot statistically signiﬁcant
(P = .06).
The basic idea of this study was to treat the two groups
exactly the same in every detail except one (MIPE). The
author examined the two groups to see if the MIPE made a
diﬀerence between them. The diﬀerence between groups was
attributed to the MIPE.
Although the exact mechanism by which MIPE improves
sensation in the diabetic neuropathic foot is not precisely
known, it has been proposed that it leads to increased release
of nitric oxide and improved microcirculation for the fol-
lowing reasons
(1) NobelLaureateRobertFurchgottreportedthatphoto
energy modulates circulation, and it has been shown
that exposure to 890nm near infrared photo energy
promotes increased blood ﬂow for several hours in
rats by mediating endothelial nitric oxide synthase
[26].
(2) Photo energy absorbed by hemoglobin increases the
amount of nitric oxide in red blood cells, in the
form of nitrosothiols, and therefore MIPE is likely to
increase vasodilatation secondary to release of nitric
oxide [27].
(3) Diabetic glycosylated hemoglobin binds nitric oxide
and inhibits its release from hemoglobin at microcir-
culatory sites, and MIPE is likely to enable release of
nitric oxide from glycosylated hemoglobin [28].
Since patients with DPN often have concomitant
decreased capillary blood ﬂow to tissues of the feet and
impaired circulation to the peripheral nerves, it is plausible
that improved oxygenation and nutrition related to nitric
oxide metabolism related to MIPE could promote nerve
growth and reestablish nerve membrane potentials that had
been reduced by the hypoxic conditions associated with dia-
betes [29]. Moreover, physical therapy methods and exercise
are often used to decrease pain and increase balance in
patients with DPN. In a rat model, it was shown that exerciseISRN Rehabilitation 5
Table 2: Outcomes at baseline and 4 weeks, by intervention group (number = 35 participants)∗.
Outcome Group 1—training + MIPE∧ (n = 18) Group 2—training only (n = 17)
10-cm analogue pain scale Baseline 6.2 ± 2.1 7.3 ± 1.1
4 weeks 3.9 ± 1.8 5.1 ± 2.3
P value† ≤.05
Monoﬁlament sensation¶ Baseline 7.2 ± 1.8 8.3 ± 0.9
4 weeks 1.4 ± 2.1 7.2 ± 1.3
P value† .025 .06
Berg balance score§ Baseline 31 ± 9.27 28.58 ± 10.16
4 weeks 47.61 ± 10.16 32.52 ± 9.54
P value† ≤.05
∗Values are mean ± standard deviation.
∧MIPE: monochromatic infrared photo energy.
†Dependent sample t-test revealed statistically signiﬁcant diﬀerences within the treatment groups except within the second group diﬀerence for the sensation
measurement.
¶Possible score ranging from 0 to 10, indicative of the number of separate pedal anatomic sites where 5.07-monoﬁlament touch-pressure was not appreciated
by the participant (lower score indicative of more sensation).
§A score of 21–40 indicates balance impairment and a heightened medium risk of falling.
Table 3: Results of analysis of covariance between the groups at 4 weeks after intervention (number = 35 patients)∗.
Outcome Group 1—training + MIPE∧ (n = 18) Group 2—training only (n = 17) F statistic† P value†
10-cm analogue pain scale 3.9 ± 1.8 5.1 ± 2.3 8.16 .01
Monoﬁlament sensation¶ 1.4 ± 2.1 7.2 ± 1.3 4.2 .014
Berg balance score§ 47.61 ± 7.39 32.52 ± 9.54 12.06 .0001
∗Values are mean ± standard deviation.
∧MIPE: monochromatic infrared photo energy.
†Analysis of covariance.
¶Possible score ranging from 0 to 10, indicative of the number of separate pedal anatomic sites where 5.07-monoﬁlament touch-pressure was not appreciated
by the participant (lower score indicative of more sensation).
§A score of 21–40 indicates balance impairment and a medium risk of falling.
could reduce pain by increasing the production of endo-
genous analgesics [30].
There has been some research into the eﬃcacy of exercise
asitpertainstoincreasingbalanceinpatientswithDPN[31].
Forexample,ameta-analysisconcludedthatexercisereduced
the risk of falling and improved balance in the elderly
[32]. However, that particular study did not include those
with DPN. In another meta-analysis, investigators found
that physical therapy interventions led to minimal improve-
ments in balance or reduction in fall risk in the elderly and
those with distal neuropathy, and the authors of that report
concluded that patients continued to experience deﬁcits in
balance and sensation after the intervention [33].
Moreover, Kruse et al. [34] conducted a 12-month
randomizedcontrolledstudytoinvestigatetheeﬀectsofexer-
cise and walking intervention on balance, lower-extremity
strength, and fall incidence in 79 patients with DPN. The
training included leg strengthening and balance exercises,
and the authors of that study did not ﬁnd statistically signiﬁ-
cantdiﬀerencesintheincidenceoffallingbetweenthegroups
during followup, although they did show a small increase in
the amount of time that patients in the intervention group
could stand on one leg with their eyes closed at the 1-
year follow up, which led the investigators to conclude that
exercise may increase activity without increasing balance or
decreasing the incidence of falling. Interestingly, few authors
have found favorable results advocating the use of exercise
to increase balance and reduce the risk of falls in people
with DPN. Song et al. [35] found that a balance exercise and
trunk proprioception program improved balance and trunk
proprioception in patients with DPN. They reported statisti-
cally signiﬁcant (P<. 05) decreases in postural sway
and trunk repositioning errors, and statistically signiﬁcant
increases (P<. 05) in dynamic balance using the Berg bal-
ance scale, functional reach test, timed up and go test, and
10m walking time after balance exercise. Based on the exist-
ing literature, we feel that controversy exists in regard to
the eﬃcacy of exercise as it relates to improving balance in
patients with DPN.
There are a number of published articles [12–17] that
focus on the use of MIPE to increase balance, reduce pain,
and restore sensation in patients with DPN, although the
general conclusion of these reports is that MIPE is a recom-
mended intervention in patients with DPN. Unfortunately,
the conclusions of the existing literature are threatened by
numerous methodological shortcomings. Leonard et al. [12]
investigated the eﬀects of MIPE in regard to sensation,
pain, and balance in 18 diabetic patients with DPN, and
measured outcomes in terms of the 5.07 monoﬁlament and
the modiﬁed Michigan neuropathy screening instrument6 ISRN Rehabilitation
obtained before the ﬁrst and seventh visits, and after the
twelfth visit. Although these investigators showed improved
outcomes with MIPE, their conclusions were threatened by
the lack of a control group. Another investigation [13]c o n -
sidered the eﬀect of MIPE along with other physical therapy
interventions in 38 patients with peripheral neuropathy due
to diabetes, alcohol abuse, and peripheral vascular disease.
He assessed foot sensation and balance using the 5.07
monoﬁlament and the Tinetti assessment tool, and observed
improved sensation, increased balance, and reduced fall risk
at the end of 12 sessions and at the 3-month followup. The
major limitation of their study was, once again, the lack of
a control group, and they did not take into consideration
the potential inﬂuence that psychoactive drugs may have had
on the risk of falling, other medications, or comorbidities
(stroke, other neuropathies) which may have had on your
participants.
A third report [14] aimed to evaluate the responses of
252 patients with DPN to a health status questionnaire by
phone interview following the end of MIPE intervention
in patients >64 years of age, the participants having been
identiﬁed from insurance billing records of two providers
who used monochromatic energy devices for use at home.
After 1 year of followup, they found a reduced incidence
of falls (78%) and fear of falling (79%) at 1 month, and
increased daily living activities (72%), although the ﬁndings
of this investigation were limited by recall and ascertainment
biases-related patient memory.
Af o u r t hr e p o r t[ 15] described decreased pain, improved
sensation, and increased balance in 2239 diabetic patients
who received MIPE, balance and strengthening exercises in
a group of outpatient physical therapy centers, although
their ﬁndings were limited by the retrospective nature of the
investigation, as well as biases related to possible (and likely)
insurance coding errors. In a ﬁfth previously published
report [16], researchers performed a retrospective study to
assess the eﬀect of MIPE and therapeutic exercises in regard
to pain reduction, 5.07 monoﬁlament sensation, and Tinetti
balance scores in 272 patients (mean age 69 ± 12.3y e a r s )
with peripheral neuropathy due to a variety of etiologies,
treated at 8 diﬀerent outpatient physical therapy centers.
They also reported statistically signiﬁcant beneﬁcial eﬀects
related to the intervention, including a 38% decrease in pain,
77%improvement insensation, and73% decreaseinbalance
deﬁcits, although the validity of the results is also threatened
by the same limitations that jeopardized the ﬁndings of the
previously mentioned investigations.
Finally, a sixth published report [17]d e s c r i b e dar a n -
domized, sham-controlled clinical trial, wherein MIPE was
shown to have no eﬀect in reducing pain, improving foot
sensation, or increasing quality of life in 60 patients with
DPN. In that investigation, the participants received MIPE
at home for 40 minutes daily over 90 consecutive days, via
4 pads (dorsal and plantar foot, medial and lateral aspects
of the calf). The participants were trained to use the photo
energy machine at home, and to log their use, and they
were checked after 2 weeks of therapy to verify that the
intervention was being used correctly.
Potential limitations of this particular report include the
usual problems associated with patients logging their activ-
ities, and other biases related to unmeasured confounders.
Loss to follow up was mostly due to scheduling diﬃculties
or taking the time to participate in the study in each group.
Therefore, it cannot be argued that participants withdrew
due to the interventions. There are a number of potential
biases that could threaten the validity or conclusions, and
for these reasons we realize that future investigation remains
necessary in order to better understand the clinical value of
MIPE in the management of DPN.
Perhaps the biggest limitation of this study relates to the
fact that the author did not employ sham MIPE, and the
improvements in the dependent variables could have been
due to the placebo eﬀect. Both groups received therapeutic
exercises and balance training which may have inﬂuenced
the improvement. Moreover, the author did not undertake
an explanatory analysis, nor did we take into consideration
every independent variable that experienced clinicians may
think of as important in regard to the treatment of DPN.
For instance, the participants were not asked to change
any aspect of diet, exercise, drugs, and the author did not
analyze the potential inﬂuence of psychoactive drugs and
other intrinsic risks for falling. Moreover, the neuropathic
pain questionnaire couldhave been used instead of the visual
analogue score to measure neuropathic pain [36].
Still further, additional research is needed to more pre-
cisely identify the role that nitric oxide plays in these out-
comes, and whether or not the improvement in sensation,
pain, and balance that were observed in this 1-month fol-
lows-up study is sustained longterm. Treatment only lasted
for 4 weeks which is too short and it is questionable whether
improvement would be lasting. It is also recommend com-
paring MIPE to other photo energy modalities such as laser
to establish its superiority over these modalities. Based on
the results of this randomized, controlled clinical trial, MIPE
may be eﬀective in decreasing pain, restoring sensation, and
increasing balance in patients with DPN.
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